Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) have filed an application to the FDA for Emergency Use Authorization (EUA) for an additional COVID-19 vaccine booster dose in adults 65 years of age and older.
The two companies announced yesterday that they have submitted two real-world data sets from Israel while the omicron variant was widespread.
Pfizer notes that an additional dose of the BNT162b2 vaccine enhanced protection against infections and severe illness.
Get the full story on our sister site Drug Discovery & Development.